|
19 Jun 2020 |
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
|
|
18 Jun 2020 |
Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
|
|
18 Jun 2020 |
Genentech’s Tecentriq in Combination With Chemotherapy (Including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer
|
|
17 Jun 2020 |
CORAT Therapeutics Takes Over the Fast Track Development of a Novel COVID-19 Antibody Drug Program
|
|
17 Jun 2020 |
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
|
|
17 Jun 2020 |
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
|
|
17 Jun 2020 |
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
|
|
17 Jun 2020 |
FDA Approves First Treatment for Adult Onset Still’s Disease, a Severe and Rare Disease
|
|
17 Jun 2020 |
Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
|
|
17 Jun 2020 |
FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients
|
|
15 Jun 2020 |
Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)
|
|
15 Jun 2020 |
Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients
|
|
13 Jun 2020 |
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting
|
|
13 Jun 2020 |
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
|
|
13 Jun 2020 |
First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis
|
|
13 Jun 2020 |
ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
|
|
13 Jun 2020 |
ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
|
13 Jun 2020 |
Subcutaneous Formulation of DARZALEX®▼(Daratumumab) Combination Resulted in Deep and Rapid Haematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
|
|
12 Jun 2020 |
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
|
11 Jun 2020 |
World's first iLDC enabling ADC drug receives IND clearance by the US FDA
|
|
11 Jun 2020 |
Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19
|
|
11 Jun 2020 |
LEO Pharma Announces European Medicines Agency Acceptance of Marketing Authorization Application for tralokinumab for the Treatment of Adults With Moderate-To-Severe Atopic Dermatitis
|
|
11 Jun 2020 |
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy
|
|
10 Jun 2020 |
Twist Bioscience Partners with Serimmune to Identify SARS-CoV-2 Therapeutic Antibody Candidates
|
|
10 Jun 2020 |
Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema
|
